Royalty Pharma plc
RPRXRoyalty Pharma is a private equity investor firm founded in 1996. It purchases the rights to royalties on future drug sales. It claims to own partial rights to 7 of the top 30 selling drugs in the United States.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How RPRX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
valacyclovir | Phase 2 | HIV Infections | - | - |
Frequently asked questions
What is in Royalty Pharma plc's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Royalty Pharma plc's (RPRX) pipeline across Phase 2. Its lead program is valacyclovir (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Royalty Pharma plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Royalty Pharma plc (RPRX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RPRX biotech catalysts?→
Add RPRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Royalty Pharma plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.